Awesome positive human trial news just got announced on X: “…. Vivos Inc. announces the successful completion of patient enrollment in its 20-patient prospective clinical evaluation of the company’s IsoPet® Postoperative Precision Radionuclide Therapy for Treatment of Incomplete Histologic Margins protocol. This innovative postoperative application of IsoPet® Precision Radionuclide Therapy™ (PRnT) is designed to tre…..”